← Back to headlines
Piper Sandler Maintains Positive Outlook on BioMarin and CVS Health
Investment bank Piper Sandler has reaffirmed its overweight ratings on BioMarin Pharmaceutical and CVS Health, highlighting robust pipeline developments and stable revenue projections. The firm also noted that ongoing policy discussions around the 340B drug discount program present manageable risks for CVS.
Sources
Showing 0 of 1 sources
No articles available in your preferred languages.
1 article available in other languages below.
